PhIII Steroids+Tyrosine KI Induction w/Chemo or Blinatumomab for New Diagnose BCR-ABL+ ALL in Adults

Cancer
Deepa Jeyakumar
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Lymphoid Leukemia

Study Description

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

Eligibility

You can participate in this study if you

  • are must be ≥ 18 and ≤ 75 years of age.

You cannot participate in this study if you

  • are pregnant or breast-feeding
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.